EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Selective Targeting of STAT6: Recent Advances and Future Perspectives

Hua Liu, Feihai Ma, Zexu Wang, Zhiyu Li, Jinlei Bian, Zeli Yuan, Tizhi Wu iD

Medicinal Research Reviews · 2026-11 · 46 (6) · 1623-1648

DOI: 10.1002/med.70069 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 05.06.2026. Verfasst von Hua Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Jiangsu Key Laboratory of Drug Design and Optimization, School of Pharmacy, China Pharmaceutical University, Nanji…. Hauptthemen laut MEDLINE: STAT6 Transcription Factor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 154 Literaturangaben. Gefördert von: Postdoctoral Fellowship Program and China Postdoctoral Science Foundation, Jiangsu Distinguished Postdoctoral Program, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Signal transducer and activator of transcription 6 (STAT6) is a key transcription factor in cytokine signaling, serving as the central effector of the IL‐4 and IL‐13 pathways. STAT6 orchestrates a range of physiological and pathological processes, including immune homeostasis and tumor development, making it an attractive therapeutic target for Th2‐driven diseases and certain cancers. While the development of STAT6‐directed agents remains at an early stage, the rapid clinical progression of the highly selective degrader KT‐621 has revitalized interest in this target. In this review, we systematically summarize recent advances in STAT6 inhibitors and degraders, with a focus on structural features, design strategies, and biological evaluation. We also highlight current challenges and future opportunities, aiming to provide useful guidance for the discovery and optimization of next‐generation STAT6‐directed therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT6 Transcription FactorHumansAnimalsSignal Transduction

Stichwörter der Autor:innen

STAT6STAT6 inhibitors and degradersTh2‐driven diseasesstructure‐activity relationships

Substanzen

STAT6 Transcription FactorSTAT6 protein, human

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Jiangsu Key Laboratory of Drug Design and Optimization, School of Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
  • School of Pharmacy, Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Guizhou International Science & Technology Coopera…

ORCID-Profile: Tizhi Wu

Förderung

  • Postdoctoral Fellowship Program and China Postdoctoral Science Foundation
  • Jiangsu Distinguished Postdoctoral Program
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Liu, H., Ma, F., Wang, Z., Li, Z., Bian, J., Yuan, Z., & Wu, T. (2026). Selective Targeting of STAT6: Recent Advances and Future Perspectives. Medicinal Research Reviews, 46(6), 1623-1648. https://doi.org/10.1002/med.70069

Vancouver

Liu H, Ma F, Wang Z, Li Z, Bian J, Yuan Z, et al. Selective Targeting of STAT6: Recent Advances and Future Perspectives. Medicinal Research Reviews. 2026;46(6):1623-1648. doi:10.1002/med.70069

BibTeX
@article{Liu2026,
  author = {Liu, Hua and Ma, Feihai and Wang, Zexu and Li, Zhiyu and Bian, Jinlei and Yuan, Zeli and Wu, Tizhi},
  title = {Selective Targeting of STAT6: Recent Advances and Future Perspectives},
  journal = {Medicinal Research Reviews},
  year = {2026},
  volume = {46},
  number = {6},
  pages = {1623--1648},
  doi = {10.1002/med.70069}
}
Kostenlos starten →